Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Holocene Advisors LP

Holocene Advisors LP lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,802 shares of the company’s stock after selling 1,742 shares during the period. Holocene Advisors LP’s holdings in Medpace were worth $2,604,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MEDP. Signaturefd LLC lifted its holdings in shares of Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after purchasing an additional 26 shares during the last quarter. Wealth Alliance grew its stake in Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after buying an additional 27 shares during the last quarter. Centaurus Financial Inc. increased its position in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after buying an additional 29 shares during the period. Commonwealth Equity Services LLC lifted its stake in Medpace by 0.7% in the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after buying an additional 32 shares during the last quarter. Finally, Lindenwold Advisors INC boosted its holdings in shares of Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after acquiring an additional 32 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Redburn Atlantic started coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average target price of $380.56.

Medpace Stock Down 1.2 %

NASDAQ:MEDP opened at $342.30 on Friday. The business’s 50-day moving average price is $337.93 and its 200 day moving average price is $369.88. Medpace Holdings, Inc. has a 52-week low of $277.72 and a 52-week high of $459.77. The firm has a market cap of $10.64 billion, a P/E ratio of 29.97, a PEG ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.22 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.